

RENALYTIX AI

Update on non-executive director appointment

September 30, 2019

Download [full announcement](#)

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

A qualified candidate has been identified to the Company and the process of completing regulatory due diligence is nearing completion. Further announcements will be made at the appropriate time.

Enquiries

Renalytix AI plc

James McCullough, CEO

www.renalytixai.com

Via Walbrook PR or
Tel: +1 646 397 3970

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)
Peter Lees (Corporate Broking)

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780
renalytix@walbrookpr.com

Mob: 07980 541 893
07584 391 303